Shots:

• Evotec and GARDP enter into an agreement to develop novel therapies for growing   threat of antimicrobial resistance (AMR)
•  The focus of the collaboration is to combine GARDP’s clinical expertise with Evotec’s drug discovery platform to develop antibiotics for AMR and establish antibiotic discovery- development platform with portfolio of antibiotic assets
• Evotec’s anti-infective platform enabling discovery and development of vaccines to treat- prevent serious life-threatening infections arising from Gram-positive and Gram-negative bacteria including MDR organism with a collection of strains producing in-vitro and in-vivo therapies

Ref: Evotec | Image: Twitter